Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04486261
Other study ID # MCT16072020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 30, 2021
Est. completion date January 1, 2023

Study information

Verified date April 2024
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effects of a high-intensity strength training in patients with myositis with the primary outcome being quality of life (SF-36). The study is designed as a parallel group randomised controlled trial with an intervention group and a control group.


Description:

Overall aim: To investigate the effect of high-intensity strength training on quality of life, muscle strength, physical function, and disease activity in patients with myositis Study design: 60 myositis patients will be included in a 16-week high-intensity strength training study. Patients will be randomly allocated into 2 groups (strength training and control) in a 1:1 ratio. User involvement: Myositis patients has been recruited to a patient advisory board. The advisory board's objective is to give patient-oriented project feedback, thus improving the overall research project. Intervention: Two training session per week for 16 weeks. Sessions consists of 3 sets of each exercise corresponding to 10 RM. Training progression will be accounted for and training loads will be evaluated weekly. The training protocol will be a full-body protocol, i.e. all major muscle groups will be engaged during each training session. Outcomes: The primary outcome is the Physical Component Summary Measure from the quality of life questionnaire (SF-36). Secondary outcomes include strength measures, functional tests, disease activity measures, questionnaires (e.g. International physical activity questionnaire), DEXA whole body scans, blood samples and muscle biopsies.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date January 1, 2023
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Fulfilling the criteria for myositis by EULAR/ACR (Bottai et al., 2017; Lundberg et al., 2017) - = 5 mg/day Prednisolone - Stable dosage of immunosuppressive treatment for at least 1 months prior to inclusion in the study - Myositis diagnosis at least 6 months prior to inclusion in the study Exclusion Criteria: - Patients with sporadic inclusion body myositis and overlap myositis (myositis combined with another autoimmune rheumatic diseases, except Sjögren's Syndrome) - Co-morbidity preventing resistance training (severe heart/lung-disease, uncontrolled hypertension (systolic > 160mmHg, diastolic > 100mmHg), severe knee/hip arthritis) - Alcohol- and/or drug abuse. Defined by the guidelines issued by The Danish Health Authority

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High-intensity strength training
The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (3)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Odense University Hospital, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (2)

Bottai M, Tjarnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017. — View Citation

Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum In: Arthritis Rheumatol. 2018 Sep;70(9):1532. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Muscle biopsies Muscle biopsies will be taken on a selected number of subjects from either the vastus lateralis or the tibialis anterior muscle, for the use in future analysis of i.e. muscle fibre size and distribution, myogenic stem cell activity, capillary density, muscle inflammation ect. 16 weeks
Other Physical activity level Will be measured by activity tracker (watch) 16 weeks
Primary Quality of life (health survey (SF-36) subscale: Physical Component Summary) Quality of life will be evaluated with the short form (36) health survey (SF-36) subscale: Physical Component Summary. The scale ranges from 0 to 100 where 100 is the highest score. 16 weeks
Secondary Leg power Power rig 16 weeks
Secondary Handgrip strength Measured by a handheld dynamometer 16 weeks
Secondary Functional Index 3 A test of muscle strength in a series of muscles, carried out by the physician or physiotherapist 16 weeks
Secondary 30 seconds chair rise Participants are instructed to stand up and sit down on a chair as many times as possible in 30 sec. 16 weeks
Secondary Timed up-and-go Participants are instructed to rise from a chair walk 3 m forward, pass a marking and return to the chair and sit down as fast as possible 16 weeks
Secondary 2-minute walk test A 2-min maximal walk test where the participant is encouraged to cover the greatest distance possible. 16 weeks
Secondary Balance Short physical performance battery - balance part 16 weeks
Secondary Whole-body, appendicular and lower-limb lean mass Measured by Dual-energy X-ray absorptiometry 16 weeks
Secondary Fat-free mass, body fat and total mass Measured by bioimpedance 16 weeks
Secondary Physician Global Activity Physician's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease activity 16 weeks
Secondary Patient Global Activity Patient's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease activity. 16 weeks
Secondary Extra-muscular Disease Activity An assessment tool used by the physician to evaluate disease activity in various organ systems via a scoring system and a 0-10 cm scale, where the higher score indicates higher disease activity. 16 weeks
Secondary Manual muscle test 8 A test of muscle strength in a series of muscles, carried out by the physician 16 weeks
Secondary Health Assessment Questionnaire (HAQ) HAQ is a questionnaire to evaluate patient reported disability. It has 8 categories with a range of questions. Each question is scored from 0 to 3 where 0 is no disability and 3 is unable to do. 16 weeks
Secondary Physician Global assessment of disease damage Physician's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease damage. 16 weeks
Secondary Patient Global assessment of disease damage Patient's overall assessment on a single 0-10 cm scale, where the higher score indicates higher disease damage. 16 weeks
Secondary Medical history Questionnaire:
Basic cardiovascular questionnaire concerning medical conditions, current medication, heart symptoms and smoking habits
16 weeks
Secondary Self-perceived physical activity levels International Physical Activity Questionnaire - long 16 weeks
Secondary Quality of life (health survey (SF-36) subscale: Mental component summary) Quality of life will be evaluated with the short form (36) health survey (SF-36) subscale: Mental Component Summary. The scale ranges from 0 to 100 where 100 is the highest score. 16 weeks
Secondary Body mass index (BMI) Weight will be measured by scale (kg). Height will be measured by measuring (m). BMI will be derived from weight and height (kg/m^2) 16 weeks
Secondary Systolic and diastolic blood pressure Measured by blood pressure monitor 16 weeks
Secondary Blood samples (analysis of markers of af disease activity) Plasma analysis: lipid profile, HbA1c, troponins, NT-proBNP, creatine kinase 16 weeks
Secondary Electrocardiography (ECG) Standard 12-lead ECG at 25 mm/s is recorded and analyzed according to standard published criteria (48-50). According to the Minnesota coding the PQ-interval is measured and presence of 1st, 2nd (including Mobitz type 1 and 2), and 3rd degree of AV block are noted. Additional measures will include: P-wave duration (= 2.5 mm in any of leads II, III, aVF), QRS duration (= 120 ms in any of leads I, II, III, aVL, aVF), QTc duration (> 450 ms), atrial fibrillation and flutter. 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Not yet recruiting NCT06284954 - A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis Phase 2
Completed NCT01906372 - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Phase 2
Completed NCT01813617 - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Completed NCT00004357 - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Phase 2
Recruiting NCT05832034 - Add-on Intravenous Immunoglobulins in Early Myositis Phase 2
Recruiting NCT05979441 - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy Phase 3
Not yet recruiting NCT05027152 - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties N/A
Active, not recruiting NCT04723303 - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) Early Phase 1
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT05437263 - A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis Phase 3
Active, not recruiting NCT04044690 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) Phase 3
Recruiting NCT05523167 - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. Phase 2/Phase 3
Not yet recruiting NCT06004817 - Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Recruiting NCT03324152 - Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis N/A
Completed NCT02043548 - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Phase 2
Completed NCT03414086 - Predictor of Clinical Response to Acthar in Myositis
Completed NCT04628936 - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. Phase 2
Recruiting NCT03293615 - Exercise Capacity of Patients With Dermatomyosis N/A